ALTACHEM RECEIVES CLEARANCE TO BEGIN PHASE I TRIAL

Altachem Pharma has received clearance from the Therapeutic Products Directorate of Health Canada to initiate a Phase I clinical trial to investigate the topical application of its lead photodynamic therapy (PDT) compound ACP-SL017 as a treatment for actinic keratosis, a potentially serious precancerous skin condition.

This clinical trial is a controlled, randomized, open-label, dose-escalation study for the topical application of ACP-SL017 topical gel to patients with the condition. The study is designed to determine the cutaneous and systemic toxicity of topically applied ACP-SL017 with and without photoactivation, and to evaluate clinically and pathologically the therapeutic effect of applying PDT to actinic keratosis using photoactivated ACP-SL017.